Hypereosinophilic Syndrome – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hypereosinophilic Syndrome – Pipeline Review, H2 2016’, provides an overview of the Hypereosinophilic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome

The report reviews pipeline therapeutics for Hypereosinophilic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypereosinophilic Syndrome therapeutics and enlists all their major and minor projects

The report assesses Hypereosinophilic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypereosinophilic Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bristol-Myers Squibb Company

GlaxoSmithKline Plc

Knopp Biosciences LLC

Kyowa Hakko Kirin Co Ltd

Stemline Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypereosinophilic Syndrome Overview 6

Therapeutics Development 7

Pipeline Products for Hypereosinophilic Syndrome - Overview 7

Hypereosinophilic Syndrome - Therapeutics under Development by Companies 8

Hypereosinophilic Syndrome - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Hypereosinophilic Syndrome - Products under Development by Companies 11

Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development 12

Bristol-Myers Squibb Company 12

GlaxoSmithKline Plc 13

Knopp Biosciences LLC 14

Kyowa Hakko Kirin Co Ltd 15

Stemline Therapeutics Inc 16

Hypereosinophilic Syndrome - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

benralizumab - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

dasatinib - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

dexpramipexole dihydrochloride - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

mepolizumab - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

SL-401 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Hypereosinophilic Syndrome - Dormant Projects 48

Hypereosinophilic Syndrome - Product Development Milestones 49

Featured News & Press Releases 49

Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole 49

Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome 49

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Tables

List of Tables

Number of Products under Development for Hypereosinophilic Syndrome, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Hypereosinophilic Syndrome – Pipeline by Bristol-Myers Squibb Company, H2 2016 12

Hypereosinophilic Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2016 13

Hypereosinophilic Syndrome – Pipeline by Knopp Biosciences LLC, H2 2016 14

Hypereosinophilic Syndrome – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 15

Hypereosinophilic Syndrome – Pipeline by Stemline Therapeutics Inc, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Hypereosinophilic Syndrome – Dormant Projects, H2 2016 48

List of Figures

List of Figures

Number of Products under Development for Hypereosinophilic Syndrome, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Top 10 Targets, H2 2016 18

Number of Products by Stage and Top 10 Targets, H2 2016 18

Number of Products by Top 10 Mechanism of Actions, H2 2016 20

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports